About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2014 (2014), Article ID 481071, 14 pages
http://dx.doi.org/10.1155/2014/481071
Research Article

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

1Policy Analysis Inc. (PAI), Four Davis Court, Brookline, MA 02445, USA
2GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK
3GlaxoSmithKline, 7333 Mississauga Road, Mississauga, ON, Canada L5N 6L4
4University of Toronto, 144 College Street, Toronto, ON, Canada M5S 3M2
5York Health Economics Consortium, Level 2, Market Square, University of York, Heslington, York YO10 5NH, UK

Received 20 December 2013; Accepted 3 April 2014; Published 12 June 2014

Academic Editor: Antoine Italiano

Copyright © 2014 Jordan Amdahl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Jordan Amdahl, Stephanie C. Manson, Robert Isbell, et al., “Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom,” Sarcoma, vol. 2014, Article ID 481071, 14 pages, 2014. doi:10.1155/2014/481071